BRIEF published on 05/05/2025 at 09:10, 1 year 3 months ago BioNxt Solutions obtient l'acceptation de son brevet auprès de l'Organisation eurasienne des brevets Innovation Maladies Auto-immunes Solutions BioNxt Administration De Médicaments Brevet Eurasien
PRESS RELEASE published on 05/05/2025 at 09:05, 1 year 3 months ago BioNxt Solutions Reports Expanded Patent Protection from the Eurasian Patent Organization BioNxt Solutions Inc. announces acceptance of its first national level patent filing by Eurasian Patent Organization, covering sublingual drug delivery for neurodegenerative diseases BioNxt Solutions Inc. Patent Filing Neurodegenerative Diseases Sublingual Delivery Eurasian Patent Organization
BRIEF published on 05/02/2025 at 01:55, 1 year 3 months ago BioNxt Solutions Delays 2024 Annual Financial Statement Filing Management Cease Trade Order Healthcare Innovation Financial Statements Delay Annual Filings BioNxt Solutions
BRIEF published on 05/02/2025 at 01:55, 1 year 3 months ago BioNxt Solutions retarde le dépôt de ses états financiers annuels pour 2024 Dépôts Annuels Solutions BioNxt Retard Des États Financiers Innovation Dans Le Domaine Des Soins De Santé Ordonnance De Cessation D'opérations De La Direction
PRESS RELEASE published on 05/02/2025 at 01:50, 1 year 3 months ago BioNxt Solutions Announces Delay In Filing 2024 Annual Financial Statements BioNxt Solutions Inc. announces delay in filing annual financial statements for year ended December 31, 2024. Company working on completing filings by June 28, 2025, under management cease trade order Financial Statements Management Cease Trade Order BioNxt Solutions Inc. Delay Regulatory Authorities
BRIEF published on 04/23/2025 at 09:10, 1 year 3 months ago BioNxt Solutions Advances in MS Treatment Study Multiple Sclerosis Cladribine Drug Delivery Innovation BioNxt Solutions Bioequivalence Study
BRIEF published on 04/23/2025 at 09:10, 1 year 3 months ago BioNxt Solutions progresse dans une étude sur le traitement de la sclérose en plaques Sclérose En Plaques Cladribine Solutions BioNxt Étude De Bioéquivalence Innovation En Matière D'administration De Médicaments
PRESS RELEASE published on 04/23/2025 at 09:05, 1 year 3 months ago BioNxt Solutions Prepares for Human Bioequivalence Study For MS BioNxt Solutions Inc. reports advanced preparation for human bioequivalence study of BNT23001, a novel sublingual thin-film Cladribine formulation for Multiple Sclerosis treatment BioNxt Solutions Inc. Multiple Sclerosis Treatment Sublingual Thin-Film BNT23001 Human Bioequivalence Study
BRIEF published on 03/15/2025 at 00:05, 1 year 4 months ago BioNxt Solutions Closes Final Tranche of Convertible Debenture Offering Private Placement Convertible Debenture Warrants Financing BioNxt Solutions
BRIEF published on 03/15/2025 at 00:05, 1 year 4 months ago BioNxt Solutions clôture la dernière tranche de son offre d'obligations convertibles Financement Placement Privé Mandats Obligation Convertible Solutions BioNxt
Published on 08/07/2026 at 23:15, 20 hours 53 minutes ago Faraday Copper Reports Second Quarter 2026 Financial Results
Published on 08/07/2026 at 23:00, 21 hours 8 minutes ago Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing
Published on 08/07/2026 at 22:30, 21 hours 38 minutes ago UraniumX Deploys $3.8 Million to Athabasca Basin Exploration
Published on 08/07/2026 at 22:15, 21 hours 53 minutes ago Noram Lithium Engages 1353656 BC Ltd. for Marketing and Management Consulting Services
Published on 08/08/2026 at 16:25, 3 hours 43 minutes ago Bybit Sues North Korea and Lazarus Group, Secures Preliminary Injunction Freezing Stolen Assets in Landmark Crypto Asset Recovery Effort
Published on 08/07/2026 at 23:21, 20 hours 47 minutes ago EQS-Adhoc: Northern Data Group reports Q2 2026 including the adverse fair value movement on contingent consideration
Published on 08/07/2026 at 19:15, 1 day ago ABO Energy Agrees Sale of Its Polish and Hungarian Subsidiaries
Published on 08/07/2026 at 18:10, 1 day 1 hour ago Stabilus SE: Andreas Jaeger steps down as Chief Financial Officer at his own request
Published on 08/07/2026 at 18:54, 1 day 1 hour ago Covivio - Déclaration des transactions sur actions propres réalisées du 03 août 2026 au 07 août 2026
Published on 08/07/2026 at 18:54, 1 day 1 hour ago Covivio - Information on Treasury shares transactions between August 3rd, 2026, and August 7th, 2026
Published on 08/07/2026 at 18:40, 1 day 1 hour ago Disclosure of transactions in own shares from August 3 to August 7, 2026
Published on 08/07/2026 at 18:40, 1 day 1 hour ago Déclaration hebdomadaire d'opérations effectuées du 3 au 7 août 2026
Published on 08/07/2026 at 18:00, 1 day 2 hours ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 juillet 2026
